SOURCE: Crown Marketing

January 24, 2013 08:00 ET

Crown Marketing Reviews Licensing Technology for Nutraceutical and Supplement Market

CHAPEL HILL, NC--(Marketwire - Jan 24, 2013) - Crown Marketing (OTCQB: CWNM) is pleased to announce that it is in discussions to grant non-exclusive licenses of its Controlled Drug Delivery Technology (CDDT) to Nutraceutical and Supplement Companies. 

"It's a good fit with nutraceuticals in that it can increase the bio-availability of many of the compounds currently in use," said Chris Francis, Director of Business Development. "We are able to control the release with respect to amount dosed and the amount of time it is released into the body." He continued, "This technology will give Nutraceutical companies the ability to differentiate themselves from the competition, and thereby increase their sales and margins."

According to a study from Transparency Market Research, the global nutraceutical product market reached 142.1 billion in 2011 and is expected to reach 204.8 billion by 2017, growing at a CAGR of 6.3% from 2012 to 2017. 

About The Company:

Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles diffusion through precise mathematical formulas.
The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels. 

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at:

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

Contact Information

  • Contact:
    Charles Van Der Ross